CRISPR Therapeutics (CRSP) Up 11.1% Since Last Earnings Report: Can It Continue?

Company Overview - CRISPR Therapeutics AG (CRSP) shares have increased by approximately 11.1% over the past month, outperforming the S&P 500 [1] - The most recent earnings report is essential for understanding the key drivers behind this performance [1] Earnings Estimates - Estimates for CRISPR Therapeutics have trended downward over the past month, with a consensus estimate shift of -20.48% [2] - The stock currently holds a Zacks Rank 3 (Hold), indicating an expectation of in-line returns in the coming months [4] VGM Scores - CRISPR Therapeutics has an average Growth Score of C and a Momentum Score of B, but a low Value Score of F, placing it in the bottom 20% for this investment strategy [3] - The overall aggregate VGM Score for the stock is D, which is relevant for investors not focused on a single strategy [3] Industry Performance - CRISPR Therapeutics is part of the Zacks Medical - Biomedical and Genetics industry, where Exact Sciences (EXAS) has gained 3.6% over the past month [5] - Exact Sciences reported revenues of $706.78 million for the last quarter, reflecting a year-over-year increase of +10.9% [5] - The expected loss for Exact Sciences in the current quarter is $0.08 per share, with a year-over-year change of +11.1% [6]